Drug Trial Radar · NCT00619359
Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
Last checked: Nov 19, 2026Latest source record: Mar 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,322
Actual
Start
Feb 2008
Primary completion
Jun 2009
Study completion Jun 2009
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 21, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to examine the safety, tolerability, and efficacy of MK0517 to prevent Chemotherapy-Induced Nausea and Vomiting (CINV) associated with Cisplatin chemotherapy.
Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV)
Interventions
Comparator: fosaprepitant dimeglumineDrug
single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.
Comparator: AprepitantDrug
Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).
DexamethasoneDrug
Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.
DexamethasoneDrug
Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.
OndansetronDrug
single IV dose of 32 mg of ondansetron on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin).Time frame: Overall (in the 120 hours following initiation of cisplatin chemotherapy).
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.